A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)

NCT07282574 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

360

Enrollment

INDUSTRY

Sponsor class

Conditions

Progressive Multiple Sclerosis

Interventions

DRUG: RO7268489
DRUG: Ocrelizumab
DRUG: Placebo

Sponsor

Hoffmann-La Roche